AbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Abbvie (ABBV) PT Lowered to $187 at Barclays
April 29, 2024 5:22 AM EDTBarclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.
The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."
... MoreAbbVie (ABBV) Tops Q1 EPS by 4c, Raises Guidance
April 26, 2024 7:36 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.31, $0.04 better than the analyst estimate of $2.27. Revenue for the quarter came in at $12.31 billion versus the consensus estimate of $11.93 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of $11.13-$11.33, versus the consensus of $11.10.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More